NeuBase Therapeutics, Inc.

2023 Q4 Form 10-Q Financial Statement

#000155837023018577 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $12.57M $23.15M
YoY Change -45.71% -56.23%
Cash & Equivalents $12.57M $23.15M
Short-Term Investments $0.00
Other Short-Term Assets $780.0K $1.496M
YoY Change -47.86% -26.5%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $13.35M $24.65M
YoY Change -45.83% -55.13%
LONG-TERM ASSETS
Property, Plant & Equipment $79.67K $2.157M
YoY Change -96.31% -12.46%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change -100.0%
Other Assets $130.0K $0.00
YoY Change -100.0%
Total Long-Term Assets $5.269M $8.045M
YoY Change -34.5% -12.93%
TOTAL ASSETS
Total Short-Term Assets $13.35M $24.65M
Total Long-Term Assets $5.269M $8.045M
Total Assets $18.62M $32.69M
YoY Change -43.04% -49.05%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $258.6K $1.843M
YoY Change -85.97% 1.94%
Accrued Expenses $462.2K $1.663M
YoY Change -72.2% -4.87%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change -100.0%
Long-Term Debt Due $0.00 $107.6K
YoY Change -100.0% 0.0%
Total Short-Term Liabilities $4.650M $4.166M
YoY Change 11.61% -0.66%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $4.830M $5.335M
YoY Change -9.47% -7.92%
Total Long-Term Liabilities $4.830M $5.335M
YoY Change -9.47% -9.63%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.650M $4.166M
Total Long-Term Liabilities $4.830M $5.335M
Total Liabilities $9.485M $9.502M
YoY Change -0.18% -5.9%
SHAREHOLDERS EQUITY
Retained Earnings -$116.5M -$102.7M
YoY Change 13.36% 48.97%
Common Stock $373.00 $3.300K
YoY Change -88.7% 0.86%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $9.137M $23.19M
YoY Change
Total Liabilities & Shareholders Equity $18.62M $32.69M
YoY Change -43.04% -49.05%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.73
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.57
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-16.08
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2757576
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1614156
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2046477
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1620344
dei Entity Central Index Key
EntityCentralIndexKey
0001173281
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3729206
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1657768
CY2023Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.05
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35963
dei Entity Registrant Name
EntityRegistrantName
NEUBASE THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-5622433
dei Entity Address Address Line1
EntityAddressAddressLine1
350 Technology Drive
dei Entity Address City Or Town
EntityAddressCityOrTown
Pittsburgh
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
15219
dei City Area Code
CityAreaCode
412
dei Local Phone Number
LocalPhoneNumber
763-3350
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
dei Trading Symbol
TradingSymbol
NBSE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3729206
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
12570359
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17386326
CY2023Q3 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
429140
CY2022Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
0
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
259583
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
188266
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
92950
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
391655
CY2023Q3 us-gaap Assets Current
AssetsCurrent
13352032
CY2022Q4 us-gaap Assets Current
AssetsCurrent
17966247
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
79665
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1934100
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5064184
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5409574
CY2023Q3 us-gaap Security Deposit
SecurityDeposit
125391
CY2022Q4 us-gaap Security Deposit
SecurityDeposit
273215
CY2023Q3 nbse Other Assets Total
OtherAssetsTotal
5189575
CY2022Q4 nbse Other Assets Total
OtherAssetsTotal
5682789
CY2023Q3 us-gaap Assets
Assets
18621272
CY2022Q4 us-gaap Assets
Assets
25583136
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
258644
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
369505
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
462186
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1227656
CY2023Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
3428601
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
500817
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
469118
CY2023Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
0
CY2022Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
78987
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4650248
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2145266
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4834348
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
5214074
CY2023Q3 us-gaap Liabilities
Liabilities
9484596
CY2022Q4 us-gaap Liabilities
Liabilities
7359340
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3729206
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1657768
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
373
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
166
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
125610714
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
125337022
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-116474411
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-107113392
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
9136676
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
18223796
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
18621272
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25583136
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1203020
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2236325
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6523996
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8934037
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
387564
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5487056
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2912094
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17079335
CY2023Q3 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
1222592
CY2022Q3 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
0
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
1229319
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
0
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
2813176
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
7723381
us-gaap Operating Expenses
OperatingExpenses
10665409
us-gaap Operating Expenses
OperatingExpenses
26013372
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2813176
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7723381
us-gaap Operating Income Loss
OperatingIncomeLoss
-10665409
us-gaap Operating Income Loss
OperatingIncomeLoss
-26013372
CY2023Q3 us-gaap Interest Expense
InterestExpense
122
CY2022Q3 us-gaap Interest Expense
InterestExpense
2693
us-gaap Interest Expense
InterestExpense
3206
us-gaap Interest Expense
InterestExpense
8828
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
162924
CY2022Q3 us-gaap Interest Income Other
InterestIncomeOther
106710
us-gaap Interest Income Other
InterestIncomeOther
457349
us-gaap Interest Income Other
InterestIncomeOther
147302
CY2023Q3 nbse Gain Loss On Issuance Of Common Stock And Warrants
GainLossOnIssuanceOfCommonStockAndWarrants
-660
CY2022Q3 nbse Gain Loss On Issuance Of Common Stock And Warrants
GainLossOnIssuanceOfCommonStockAndWarrants
0
nbse Gain Loss On Issuance Of Common Stock And Warrants
GainLossOnIssuanceOfCommonStockAndWarrants
-1312212
nbse Gain Loss On Issuance Of Common Stock And Warrants
GainLossOnIssuanceOfCommonStockAndWarrants
0
CY2023Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-810895
CY2022Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2241246
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
19027
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-12524
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-78787
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-172736
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
992064
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
91493
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1304390
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-34262
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1821112
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7631888
us-gaap Net Income Loss
NetIncomeLoss
-9361019
us-gaap Net Income Loss
NetIncomeLoss
-26047634
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.73
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.57
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-16.08
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2757576
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1614156
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2046477
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1620344
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
18223796
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
316689
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
721
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-4093113
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
14448093
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
245012
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
19
CY2023Q2 nbse Adjustments To Additional Paid In Capital Cash Paid In Lieu Of Fractional Shares From Reverse Stock Split
AdjustmentsToAdditionalPaidInCapitalCashPaidInLieuOfFractionalSharesFromReverseStockSplit
9
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-3446794
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
11246321
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-292343
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2051
CY2023Q3 nbse Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
1759
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-1821112
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
9136676
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
47134203
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
952828
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-9924029
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
38163002
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
641046
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-8491717
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
30312331
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
510612
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
825
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7631888
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
23191880
us-gaap Net Income Loss
NetIncomeLoss
-9361019
us-gaap Net Income Loss
NetIncomeLoss
-26047634
us-gaap Share Based Compensation
ShareBasedCompensation
269358
us-gaap Share Based Compensation
ShareBasedCompensation
2104485
nbse Gain Loss On Issuance Of Common Stock And Warrants
GainLossOnIssuanceOfCommonStockAndWarrants
-1312212
nbse Gain Loss On Issuance Of Common Stock And Warrants
GainLossOnIssuanceOfCommonStockAndWarrants
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-2241246
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Depreciation And Amortization
DepreciationAndAmortization
509304
us-gaap Depreciation And Amortization
DepreciationAndAmortization
585812
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-63830
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3844
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
857109
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
0
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-3
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
345390
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
391611
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-227388
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
338021
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
147824
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
-19600
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-110861
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
715284
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-765470
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-750222
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-348027
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-389082
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9094208
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-23743520
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
13447
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
347835
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
8500
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-4947
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-347835
nbse Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
4357653
nbse Proceeds From Issuance Of Common Stock And Warrants Net
ProceedsFromIssuanceOfCommonStockAndWarrantsNet
0
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1759
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
78987
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
82868
nbse Payment In Lieu Of Fractional Shares From Reverse Stock Split
PaymentInLieuOfFractionalSharesFromReverseStockSplit
9
nbse Payment In Lieu Of Fractional Shares From Reverse Stock Split
PaymentInLieuOfFractionalSharesFromReverseStockSplit
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2772
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
826
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4283188
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-82042
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-4815967
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-24173397
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
17386326
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
47326060
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
12570359
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
23152663
nbse Non Cash Activity Of Fair Value Of Warrants Issued
NonCashActivityOfFairValueOfWarrantsIssued
5669847
nbse Non Cash Activity Of Fair Value Of Warrants Issued
NonCashActivityOfFairValueOfWarrantsIssued
0
nbse Non Cash Activity Of Held For Sale Assets
NonCashActivityOfHeldForSaleAssets
429140
nbse Non Cash Activity Of Held For Sale Assets
NonCashActivityOfHeldForSaleAssets
0
nbse Right Of Use Asset In Exchange For Operating Lease Liability
RightOfUseAssetInExchangeForOperatingLeaseLiability
0
nbse Right Of Use Asset In Exchange For Operating Lease Liability
RightOfUseAssetInExchangeForOperatingLeaseLiability
164613
us-gaap Basis Of Accounting
BasisOfAccounting
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">1.  Organization, Description of Business</b><b style="font-weight:bold;"> and Liquidity</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">NeuBase Therapeutics, Inc. and its subsidiaries (the “Company” or “NeuBase”) has historically been a preclinical-stage biopharmaceutical company developing a modular peptide nucleic acid (“PNA”) antisense oligo (“PATrOL™”) platform to address genetic diseases with a single, cohesive approach. NeuBase planned to use its platform to address diseases which have a genetic source, with an initial focus on gene silencing in myotonic dystrophy type 1 (“DM1”), Huntington’s disease (“HD”), and oncology.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In October 2022, the Company announced plans to expand its focus to include the advancement of the differentiated gene editing capabilities of its platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">In August 2023, the Company announced that its Board of Directors (the “Board”) had made the determination to halt further development of the Company’s programs and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. As part of this evaluation process, the Board will explore potential strategic alternatives for the Company that may include, but are not limited to, an acquisition, merger, business combination, or other transaction.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Liquidity and Going Concern</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company has had no revenues from product sales and has incurred operating losses since inception. As of September 30, 2023, the Company had $12.6 million in cash and cash equivalents, and during the nine months ended September 30, 2023, incurred a loss from operations of $10.7 million and used $9.1 million of cash in operating activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company expects to continue to incur substantial operating losses and negative cash flows from operations for the foreseeable future and may never become profitable. Accordingly, there are material risks and uncertainties that raised substantial doubt about the Company’s ability to continue as a going concern. In August 2023, as further discussed below, the Board approved a plan to halt further development of the Company’s programs and to conduct a comprehensive exploration of strategic alternatives focused on maximizing shareholder value. This restructuring plan is expected to reduce operating expenses and extend the Company’s cash runway into the fourth quarter of calendar year 2025 based on current operating plans and estimates. Management believes it is probable that the restructuring plan will be effectively implemented within the next twelve months and that the restructuring plan, when implemented, will mitigate the conditions that gave rise to substantial doubt about the Company’s ability to continue as a going concern. Because the Company has sufficient resources on hand to fund operations through at least the next twelve months from the date these consolidated financial statements were available to be issued, the substantial doubt has been alleviated. There can be no assurance that the Company will be successful in acquiring additional funding, that the Company’s projections of its future working capital needs will prove accurate, or that any additional funding would be sufficient to continue operations in future years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company’s future liquidity and capital funding requirements will depend on numerous factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">its ability to raise additional funds to finance its operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">its ability to negotiate and consummate any transaction arising from its exploration of strategic alternatives;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">its ability to maintain compliance with the listing requirements of The Nasdaq Capital Market;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">litigation expenses and the extent and amount of any indemnification claims;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">its ability to maintain, expand and defend the scope of its intellectual property portfolio, including the amount and timing of any payments the Company may be required to make, or that it may receive, in connection with the licensing, filing, prosecution, defense and enforcement of any patents or other intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">its ability to retain its current employees and the need and ability to hire additional management;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the trading price of its common stock; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">its ability to increase the number of authorized shares outstanding to facilitate future financing events.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">The Company will likely need to raise substantial additional funds through issuance of equity or debt or completion of a licensing transaction for one or more of the Company’s pipeline assets. If the Company is unable to maintain sufficient financial resources, its business, financial condition and results of operations will be materially and adversely affected. This could affect future development and business activities and potential future clinical studies and/or other future ventures. Failure to obtain additional equity or debt financing will have a material, adverse impact on the Company’s business operations. There can be no assurance that the Company will </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">be able to obtain the needed financing on acceptable terms or at all. Additionally, any equity financings will likely have a dilutive effect on the holdings of the Company’s existing stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Change in Year End</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">On April 21, 2023, the Board approved a change in the Company’s fiscal year end from September 30 to December 31, effective for the fiscal year beginning January 1, 2023 and ending December 31, 2023.  As a result of the change in year end, the Company filed on June 5, 2023 a Transition Report on Form 10-QT for the period from October 1, 2022 through December 31, 2022.  The Company’s 2023 fiscal year will run from January 1, 2023 through December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Reverse Stock Split</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The Company effected a <span style="-sec-ix-hidden:Hidden_r3GyR8OQi0KTceFLiIIhEQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1-for-20</span></span> reverse stock split of its outstanding shares of common stock on June 14, 2023. The reverse stock split did not change the number of authorized shares of common stock or par value. All references in these condensed consolidated financial statements to shares, share prices, exercise prices, and other per share information in all periods have been adjusted, on a retroactive basis, to reflect the reverse stock split.</p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. The most significant estimates in the Company’s unaudited condensed consolidated financial statements relate to the valuation of stock-based compensation, the valuation of warrant liabilities and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based on current facts, historical experience and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">The Company assesses and updates estimates each period to reflect current information, such as the considerations related to the impacts that the current economic environment could have on its significant accounting estimates. Actual results may differ materially and adversely from these estimates. To the extent there are material differences between the estimates and actual results, the Company’s future results of operations will be affected.</span><span style="font-weight:normal;"> </span></p>
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4238584
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
390469
nbse Warrants Fair Value
WarrantsFairValue
3428601
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
5669847
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-1430351
CY2023Q2 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
4239496
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
-810895
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
3428601
CY2022Q4 nbse Prepaid Research And Development Expense
PrepaidResearchAndDevelopmentExpense
67027
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
150000
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
92950
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
174628
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
92950
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
391655
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
291384
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3326515
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
211719
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1392415
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
79665
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1934100
CY2023Q3 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
429140
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
900000
CY2023Q3 us-gaap Depreciation
Depreciation
100000
CY2022Q3 us-gaap Depreciation
Depreciation
200000
us-gaap Depreciation
Depreciation
500000
us-gaap Depreciation
Depreciation
600000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
510612
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
269358
CY2023Q3 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
87359
CY2022Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
171572
CY2022Q4 nbse Accrued Consulting Settlement Current
AccruedConsultingSettlementCurrent
225000
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
120845
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
241808
CY2022Q4 nbse Accrued Research And Development Current
AccruedResearchAndDevelopmentCurrent
20684
CY2023Q3 nbse Accrued Franchise Tax
AccruedFranchiseTax
29680
CY2022Q4 nbse Accrued Franchise Tax
AccruedFranchiseTax
217440
CY2023Q3 nbse Accrued Restructuring Cost
AccruedRestructuringCost
185095
CY2022Q4 nbse Accrued Restructuring Cost
AccruedRestructuringCost
316032
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
39207
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
35120
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
462186
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1227656
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4030989
CY2022Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9006
CY2022Q4 nbse Weighted Average Exercise Price Warrants Outstanding
WeightedAverageExercisePriceWarrantsOutstanding
156.03
nbse Stock Expired During Period Warrants Expired
StockExpiredDuringPeriodWarrantsExpired
5256
nbse Weighted Average Exercise Price Warrants Expired
WeightedAverageExercisePriceWarrantsExpired
174.60
CY2023Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4030989
CY2023Q3 nbse Weighted Average Exercise Price Warrants Outstanding
WeightedAverageExercisePriceWarrantsOutstanding
2.47
nbse Weighted Average Remaining Contractual Life Warrants Outstanding
WeightedAverageRemainingContractualLifeWarrantsOutstanding
P3Y3M18D
CY2023Q3 nbse Warrants Exercisable
WarrantsExercisable
4030989
CY2023Q3 nbse Weighted Average Exercise Price Warrants Exercisable
WeightedAverageExercisePriceWarrantsExercisable
2.47
nbse Weighted Average Remaining Contractual Life Warrants Exercisable
WeightedAverageRemainingContractualLifeWarrantsExercisable
P3Y3M18D
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
-292343
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2104485
nbse Stock Based Compensation Expense Reversal
StockBasedCompensationExpenseReversal
400000
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
365287
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
53.27
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1875
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
4.34
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
125984
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.02
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
44693
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
66.51
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
196485
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
83.93
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y9M21D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
151137
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
93.71
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P3Y9M25D
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
600000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y7M13D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.21
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
23.31
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.823
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.852
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.737
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.785
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.035
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.040
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.014
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.034
CY2023Q3 us-gaap Restructuring Costs
RestructuringCosts
365483
us-gaap Restructuring Costs
RestructuringCosts
372210
CY2023Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
857109
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
857109
CY2023Q3 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
1222592
us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
1229319
CY2022Q4 nbse Accrued Restructuring Cost
AccruedRestructuringCost
316032
us-gaap Restructuring Charges
RestructuringCharges
372210
us-gaap Payments For Restructuring
PaymentsForRestructuring
503147
CY2023Q3 nbse Accrued Restructuring Cost
AccruedRestructuringCost
185095
us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
900000
CY2023Q3 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
900000

Files In Submission

Name View Source Status
nbse-20230930_cal.xml Edgar Link unprocessable
0001558370-23-018577-index-headers.html Edgar Link pending
0001558370-23-018577-index.html Edgar Link pending
0001558370-23-018577.txt Edgar Link pending
0001558370-23-018577-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nbse-20230930.xsd Edgar Link pending
nbse-20230930x10q.htm Edgar Link pending
nbse-20230930xex31d1.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nbse-20230930x10q_htm.xml Edgar Link completed
nbse-20230930xex31d2.htm Edgar Link pending
nbse-20230930xex32d1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
nbse-20230930_def.xml Edgar Link unprocessable
nbse-20230930_lab.xml Edgar Link unprocessable
nbse-20230930_pre.xml Edgar Link unprocessable